Neurotransmitter release is a key event in neuronal communication. Central components of the release apparatus are the SNARE proteins syntaxin-1, synaptobrevin-2 and SNAP-25, which form a stable fourhelix bundle called the SNARE complex through their SNARE motifs 1 . Formation of the SNARE complex is key for membrane fusion 2 . In addition to the SNAREs, the exquisitely precise timing and high speed of neurotransmitter release require a diversity of specialized proteins including complexins, among others 3,4 .
a r t i c l e s
Neurotransmitter release is a key event in neuronal communication. Central components of the release apparatus are the SNARE proteins syntaxin-1, synaptobrevin-2 and SNAP-25, which form a stable fourhelix bundle called the SNARE complex through their SNARE motifs 1 . Formation of the SNARE complex is key for membrane fusion 2 . In addition to the SNAREs, the exquisitely precise timing and high speed of neurotransmitter release require a diversity of specialized proteins including complexins, among others 3, 4 .
Complexins constitute a family of neuronal SNARE complex-binding proteins [5] [6] [7] [8] that have no tertiary structure in solution 9 but contain distinct functional domains (Fig. 1a) . They bind the tertiary SNARE complex with high affinity [10] [11] [12] through a central α-helix 13, 14 . This central α-helix is preceded by an accessory α-helix that does not contact the SNARE complex 13 . The precise role of complexins in exocytosis has been controversial 15 . Genetic deletion of complexin in Drosophila melanogaster and knockdown of complexins by RNA interference in mouse cortical neurons both lead to a decrease in evoked release and an increase in spontaneous release 16, 17 . In contrast, knockout of complexin genes in mice causes a reduction in evoked and spontaneous release at multiple central synapses [18] [19] [20] as well as a decrease in Ca 2+ -triggered exocytosis in adrenal chromaffin cells 21 . Moreover, in vitro lipid mixing and cell-cell fusion assays have suggested that complexins inhibit 22, 23 or stimulate 24, 25 membrane fusion. These data suggest that complexins may have both facilitatory and inhibitory functions.
Indeed, in vivo structure-function analyses and cross-species rescue experiments show that both murine and Drosophila complexins contain similar functional domains that can facilitate or inhibit exocytosis 26, 27 . Binding of the central α-helix to the SNARE complex is necessary but not sufficient for complexin function 21, 26, 27 . The N terminus of complexins facilitates release, whereas the accessory α-helix inhibits release 26, 27 . Chimeric analyses reveal that the strength of facilitation or inhibition associated with each domain is different between murine and Drosophila complexins, leading to apparently different phenotypes in mice and flies lacking complexins 27 .
The emerging picture is that complexins have dual roles in neurotransmitter release by activating and inhibiting vesicle fusion via distinct domains 26 . However, the molecular mechanism underlying the crucial facilitatory function of the complexin N terminus is unclear. The N terminus of complexins has been speculated to interact with lipid membranes 17, 26 , but no such biochemical interaction has been reported. Furthermore, a widespread model proposes that complexins clamp vesicles at the primed state, and the Ca 2+ sensor Syt1 releases the inhibition upon Ca 2+ influx 22, 23, 28, 29 . However, the nature of the interplay between complexins and Syt1 in neurotransmitter release is still debated 4, 30 , and it is unclear whether complexin function is strictly coupled to Syt1 (refs. 24,26) .
To address these questions, we performed physiological and biophysical analyses of complexin I (CplxI), a major paralog in the mouse brain. We find that the N terminus of CplxI binds to the C terminus of the SNARE complex, and mutations that disrupt this interaction specifically abolish the facilitatory function of CplxI in hippocampal neurons. We show that this interaction increases synaptic-vesicle a r t i c l e s fusogenicity at a step that may precede Ca 2+ triggering. Moreover, genetic experiments crossing complexin-and Syt1-null mice show that complexins facilitate neurotransmitter release even in the absence of Syt1. Thus, complexins may cooperate with Syt1 but can function independently of this Ca 2+ sensor.
RESULTS
To identify key functional residues in the CplxI N terminus, we used a knockout-rescue approach 26 . We used cultured autaptic hippocampal neurons from CplxI/II double-knockout (CplxI/II DKO) or CplxI/II/III triple-knockout (CplxI/II/III TKO) mice because CplxI and CplxII are the major complexin paralogs in the mouse brain, and CplxI/II DKO and CplxI/II/III TKO hippocampal neurons show indistinguishable phenotypes 19 . CplxI/II DKO and CplxI/II/III TKO are referred together as Cplx KO unless indicated otherwise.
Overexpression of wild-type (WT) CplxI completely rescues the transmitter-release defects of CplxI/II DKO neurons and does not interfere with release in WT neurons 26 . We therefore rescued Cplx KO neurons by different CplxI variants and compared them to those rescued by WT CplxI (control). Western blotting shows that the expression levels of different CplxI variants were 3-to 6-fold greater than that of endogenous CplxI (Supplementary Fig. 1 ). Immunostaining reveals that all of the CplxI variants were diffusely distributed throughout both axonal and dendritic processes and were present at presynaptic termini (Supplementary Fig. 2 ). To allow for comparisons of different CplxI variants across different rescue experiments, we normalized the data to the mean values of the corresponding control neurons (black dashed lines and error bars in Figs. 1 and 2) . We often included Cplx KO neurons only expressing enhanced green fluorescent protein (eGFP) as negative controls. All the data from Cplx KO neurons are pooled together and shown in Figures 1 and 2 , as the normalized data of Cplx KO neurons are not significantly different across experiments (P > 0.05 for all groups).
Facilitatory role of the CplxI N terminus
Deletion of the first 26 residues of CplxI (denoted as CplxI ) abolishes its facilitatory function in CplxI/II DKO neurons 26 . To narrow down the critical regions, we generated two additional N-terminal deletion mutants, CplxI and CplxI . In response to an action potential, the excitatory postsynaptic current (EPSC) amplitude of Cplx KO neurons is reduced about 50% compared to that of WT neurons 18, 19 . This defect is fully rescued by the overexpression of WT CplxI 26 ( Fig. 1b; Cplx KO: 4.2 ± 0.3 nA, n = 147; corresponding WT CplxI rescue: 8.7 ± 0.6 nA, n = 142, P < 0.0001). In contrast, both CplxI and CplxI failed to rescue the decreased evoked release of Cplx KO neurons ( Fig. 1b ; CplxI 16-134 rescue: 3.1 ± 0.4 nA, n = 25; corresponding WT CplxI rescue: 5.8 ± 1.0 nA, n = 18, P < 0.01; CplxI 8-134 rescue: 2.8 ± 0.3 nA, n = 37; corresponding WT CplxI rescue: 5.5 ± 0.6 nA, n = 30, P < 0.001).
In response to a train of high-frequency repetitive stimulations, the synaptic responses of WT neurons show depression, whereas those of Cplx KO neurons show initial facilitation 18, 19 (Fig. 1c,d ), indicating that the release probability is decreased in Cplx KO neurons. Overexpression of WT CplxI converts synaptic facilitation to synaptic depression, whereas both CplxI and CplxI failed to rescue Cplx KO neurons (Fig. 1c,d) .
To directly assess the Ca 2+ -triggered release efficacy, we determined vesicular release probability (P vr ), the fraction of readily releasable pool (RRP) released by one action potential. We measured RRP sizes by hypertonic sucrose solution 31 . RRP size is not altered in Cplx KO neurons 18, 19 , and neither CplxI nor CplxI significantly changed RRP size (data not shown, P > 0.4 for both mutants when compared to WT CplxI). Consequently, overexpression of WT CplxI rescued the decreased P vr of Cplx KO neurons, whereas CplxI and CplxI did not (Fig. 1e) .
To examine the apparent Ca 2+ sensitivity of release, we changed the external standard Ca 2+ concentrations (4 mM Ca 2+ , 4 mM Mg 2+ ) to high (12 mM Ca 2+ , 1 mM Mg 2+ ) or low Ca 2+ concentrations (1 mM Ca 2+ , 1 mM Mg 2+ ), and measured EPSC amplitude potentiation or depression, respectively (Fig. 1f) . Cplx KO neurons show greater potentiation or depression upon elevation or lowering of Ca 2+ concentrations, respectively, than WT neurons, indicating a lower apparent sensitivity to Ca 2+ (refs. 19,26) . The reduced Ca 2+ sensitivity of Cplx KO neurons was rescued by WT CplxI but not by CplxI or CplxI (Fig. 1g,h ). P vr , paired-pulsed ratio and apparent Ca 2+ sensitivity of Cplx KO neurons rescued by CplxI or CplxI do not significantly differ from those of Cplx KO neurons (Fig. 1d,e,g, a r t i c l e s P > 0.05 for all parameters). Collectively, these results indicate that the N terminus is essential for CplxI to facilitate Ca 2+ -triggered neurotransmitter release, and the facilitatory function of CplxI involves a stretch of seven residues at its very N terminus.
N-terminal point mutations impair CplxI facilitatory function
We next screened a series of point mutations in the very N terminus of CplxI, guided in part by the realization that the N terminus of CplxI can form an amphipathic α-helix (Fig. 2a) . The sequence in this region is relatively conserved across paralogs and orthologs, and the potential to form an amphipathic α-helix is conserved in all of them (Fig. 2b) .
Mutation of residues 3-6 (F3A V4A M5A K6Q) abolished the rescue of Cplx KO neurons in any of the measured parameters ( Fig. 2c-f) . Unexpectedly, mutating the most conserved residue, Phe3 (ref. 8) , to alanine (F3A) did not affect the ability of CplxI to rescue Cplx KO neurons (Fig. 2c-f) . However, mutating Met5 and Lys6, which are expected to contribute to the amphipathicity of the putative N-terminal α-helix, to glutamate (M5E K6E) completely abolished rescue activity (Fig. 2c-f) . A milder, single point mutation in the highly conserved residue Lys6 (K6Q) partially impaired the rescue (Fig. 2c-f) . Hence, both Met5 and Lys6 are important for the CplxI facilitatory function, and this function is abrogated when both residues are mutated.
We also examined the effect of N-terminal mutations on spontaneous neurotransmitter release. Cplx KO neurons show an ~30% reduction in miniature EPSC (mEPSC) frequency compared to WT neurons 19 , and this defect can be rescued by overexpression of WT CplxI (Fig. 3) . In contrast, the mEPSC frequencies of CplxI F3A V4A M5A K6Q-and CplxI M5E K6E-rescued Cplx KO neurons are only ~15-25% of that of WT CplxI-rescued Cplx KO neurons (Fig. 3a,b) , showing that the N-terminal mutations further suppress mEPSC frequency in Cplx KO neurons. Consistent with these results, CplxI 27-134 also suppressed mEPSC frequency in Cplx KO neurons (CplxI WT rescue: 10.4 ± 1.2 Hz, n = 33; CplxI 27-134 rescue: 3.0 ± 0.6 Hz, n = 37, P < 0.0001). The mEPSC amplitudes were slightly smaller in Cplx KO neurons and mutant CplxI-rescued Cplx KO neurons compared to that of CplxI WT-rescued Cplx KO neurons, but only the mEPSC amplitude of the CplxI F3A V4A M5A K6Q mutant reached statistical significance (Fig. 3c) . These data show that the N terminus of CplxI also facilitates spontaneous release and suggest that the N-terminal mutations do not affect the inhibitory function of complexins.
The CplxI N terminus binds to the SNARE complex C terminus
The antiparallel binding of the CplxI central α-helix to the SNARE complex 13, 14 positions the N terminus in close proximity to the site of membrane fusion. This observation and the potential of the CplxI N terminus to form a positively charged amphipathic α-helix (Fig. 2a) led us to hypothesize that, upon CplxI binding the SNARE complex 1.0 a r t i c l e s through the central α-helix, the CplxI N terminus may interact with the membrane(s). To test this hypothesis, we used NMR spectroscopy. Analysis of 15 N-labeled CplxI binding to unlabeled SNARE complex-containing proteoliposomes by 1 H-15 N heteronuclear single quantum correlation (HSQC) spectra is challenging because SNARE complexes aggregate on membranes unless they are reconstituted at protein-tolipid molar ratios of 1:1,000 or lower 30 , which results in difficulties in obtaining high concentrations of reconstituted SNARE complexes. Moreover, severe overlap in the CplxI 1 H-15 N HSQC spectrum (Fig. 4) limits the number of cross-peaks that can be monitored, and often there are time-dependent changes in a few C-terminal cross-peaks that can be attributed to partial proteolysis. Despite these difficulties, 1 H-15 N HSQC experiments using 2 µM 15 N-CplxI clearly show that the CplxI N terminus binds SNARE complex-containing proteoliposomes, as addition of the proteoliposomes led to broadening beyond detection of cross-peaks not only from the central α-helix but also from the N terminus (Fig. 4a,g,h) . Cross-peaks that were still observable correspond to residues that remain flexible upon proteoliposome binding, including the sequence connecting the N terminus of CplxI to the accessory α-helix.
We next studied whether the M5E K6E mutation affects proteoliposome binding. Comparison of 1 H-15 N HSQC spectra of WT and M5E K6E mutant CplxI (Fig. 4b) shows that most cross-peaks were unaltered by the mutation. We did not observe several cross-peaks from the N terminus of WT CplxI in the M5E K6E mutant, whereas new cross-peaks from the mutant N terminus appeared (labeled 'N' in Fig. 4b) . Therefore, the M5E K6E mutation causes natural perturbations in the mutated and neighboring residues but does not alter most of the protein, as expected from the lack of tertiary structure in isolated CplxI 9 . Notably, the N-terminal cross-peaks of the M5E K6E mutant were not perturbed by addition of SNARE complex-containing proteoliposomes (Fig. 4c) , whereas cross-peaks from the central α-helix still broadened beyond detection. Hence, the M5E K6E mutation preserves the binding of the CplxI central α-helix to the SNARE complex but disrupts the interaction of the N terminus with the proteoliposomes.
To determine whether binding of the CplxI N terminus to the proteoliposomes involves the SNARE complex or the phospholipids, we acquired a 1 H-15 N HSQC spectrum of WT CplxI in the presence of plain liposomes. The spectrum remained largely unaltered (Fig. 4d,g,i) . Hence, CplxI does not bind to membranes with the lipid composition used in our experiments, which includes a fraction of negatively charged phospholipids (15%) that is close to physiological. Note that CplxI was recently reported to bind membranes 32 , but the liposomes used in that study contained a much higher fraction of negatively charged phospholipids (35%). Notably, 1 H-15 N HSQC spectra of WT CplxI in the presence of soluble SNARE complex reveal broadening a r t i c l e s beyond detection of the cross-peaks from the central α-helix and the N terminus of CplxI (Fig. 4e,g,j) , showing that the N terminus interacts with the SNARE complex. Moreover, the N-terminal cross-peaks of the CplxI M5E K6E mutant were unperturbed upon addition of the soluble SNARE complex (Fig. 4f) , showing that the mutation disrupts binding of the CplxI N terminus to the SNARE complex. To test our conclusions by a different method, we used fluorescence spectroscopy with a CplxI mutant labeled at residue 12 with 7-nitrobenz-2-oxa-1,3-diazole (NBD), a probe that is highly sensitive to the environment 33 . The fluorescence spectrum of NBD-labeled CplxI mutant showed a substantial increase in intensity upon addition of the SNARE complex-containing proteoliposomes (Supplementary Fig. 3 ) that was much less dramatic than that observed upon insertion of NBD into a phospholipid bilayer 33 and is compatible with an alteration in probe environment due to SNARE-complex binding. Indeed, the soluble SNARE complex induced the same increase in NBD fluorescence intensity as the proteoliposomes, whereas plain phospholipids did not induce any significant change (Supplementary Fig. 3) , confirming that the CplxI N terminus binds to the SNARE complex.
To map the approximate binding site of the CplxI N terminus on the SNARE complex, we used 1 H-15 N transverse-relaxation optimized spectroscopy (TROSY)-enhanced HSQC spectra of four separate SNARE complex samples in which each SNARE motif was individually 2 H, 15 N labeled. We measured the paramagnetic broadening effects (PBEs) induced on the SNARE complex by the binding of a CplxI fragment (residues 2-82) bearing an A12C mutation and labeled at residue 12 with the paramagnetic probe (1-oxyl-2,2,5,5-tetramethyl-3-pyrroline-3-methyl)methanethiosulfonate (MTSL) 34 (Fig. 5) . For this purpose, we compared spectra acquired before and after reduction of MTSL with dithionite, which eliminates the broadening effects. Figure 5a shows the data obtained for the SNARE complex with 2 H, 15 N-labeled SNAP-25 C-terminal SNARE motif. Mapping of the PBEs onto the crystal structure of the CplxI 26-83 -SNARE complex (Fig. 5b) indicates that residue 12 of CplxI is located at the very C terminus of the SNARE complex, a natural location based on the position of the accessory α-helix and the fact that this helix is flexibly linked to the N terminus.
Cplx regulates the fusogenicity of synaptic vesicles
Our findings suggest a simple model in which binding of the CplxI N terminus provides critical stabilization to the SNARE complex C terminus, helping the SNAREs to exert mechanical force on the membranes to induce fusion. Binding of the CplxI N terminus may also help remove the inhibition caused by the CplxI accessory α-helix. Both models are compatible and lead to important functional predictions. For instance, the stabilization model suggests that complexins may increase the propensity of primed synaptic vesicles to fuse, a notion that is already supported by our spontaneous-release data (Fig. 3) . Moreover, both models predict that complexin function may not strictly depend on Syt1 and Ca 2+ .
To test these hypotheses, we analyzed hypertonically induced synaptic vesicle fusion, a Ca 2+ -independent process. The magnitude and kinetics of the release reflect the fusogenicity of vesicles 31, [35] [36] [37] . The standard saturating 500 mM sucrose solution depletes all fusioncompetent vesicles in WT and Cplx KO neurons 18, 19 , but we noted a slight slowing of the release kinetics and a slight reduction of peak amplitudes in Cplx KO neurons when we averaged all responses and overlaid the traces from the different groups (Fig. 6a) . This observation is consistent with our hypothesis that the fusogenicity of synaptic vesicles is reduced in Cplx KO neurons.
As a more sensitive assay, we measured the response onset latency, peak release rate and fraction of RRP released (see Online Methods) by an intermediate sucrose concentration (250 mM), which causes smaller response amplitudes with slower kinetics 36, 37 (Fig. 6a) . We found that, compared to control neurons, the response onset was delayed by ~150 ms (Fig. 6b) , and the peak release rate and the fraction of RRP released were reduced by 50% (Fig. 6c) in Cplx KO neurons. We observed similar results in autaptic striatal GABAergic neurons ( Supplementary Fig. 4 ) and mass-cultured hippocampal neurons (Supplementary Fig. 5 ). These data indicate that, in the absence of complexins, vesicle fusogenicity decreases; that is, the energy required for vesicle fusion increases in mouse neurons. Thus, murine complexins exert a facilitatory action independently of Ca 2+ triggering.
In contrast to the facilitating function of murine complexins, Drosophila complexin (DmCplx) practically abolishes both evoked and spontaneous release in Cplx KO neurons 27 , indicating that DmCplx decreases vesicle fusogenicity. Indeed, we found that the onset of the synaptic response induced by 500 mM sucrose solution was delayed by ~290 ms (Supplementary Fig. 6a) , and the peak release rate was reduced by 40% (Supplementary Fig. 6b ) in Cplx KO neurons expressing DmCplx compared to Cplx KO neurons expressing eGFP. Furthermore, 250 mM sucrose solution was barely able to induce release in Cplx KO neurons expressing DmCplx (Supplementary Fig. 6a,c,d ), consistent with a drastic increase in energy required for vesicle fusion. Together, these experiments indicate that complexins regulate synaptic-vesicle fusogenicity.
We next studied the role of the interactions of the CplxI central α-helix and N terminus with the SNARE complex in regulating vesicle fusogenicity. The delayed onset, decreased peak release rate and reduced fraction of RRP released in Cplx KO neurons were rescued by overexpression of WT . All these residues are clustered at the C terminus of the SNARE complex, and the cross-peaks from other residues in this region are not observable or overlapped. We estimate that the amide protons of these residues are within ~18 Å or less from the probe 34 . The asterisk indicates the estimated position of the MTSL probe in the bound MTSL-CplxI 2-82 A12C. a r t i c l e s CplxI (Fig. 6d,e) . In contrast, a mutant CplxI carrying two mutations (K69A Y70A) in the central α-helix, which neither binds the SNARE complex nor rescues the evoked release of Cplx KO neurons 26 , was unable to rescue Cplx KO neurons in response onset latency, peak release rate or fraction of RRP released by 250 mM sucrose solution (Fig. 6d,e) . Hence, the ability of CplxI to boost vesicle fusogenicity requires binding to the SNARE complex. Finally, a CplxI bearing the M5E K6E mutation, which disrupts the binding of the CplxI N terminus to the SNARE complex, also failed to rescue Cplx KO neurons (Fig. 6d,e and Supplementary Fig. 5) . Thus, the CplxI N-terminal interaction with the SNARE complex is essential for augmenting synaptic-vesicle fusogenicity.
Cplx functions independently and cooperatively with Syt1
A key prediction of both the stabilization and the disinhibition models is that complexins may function independently of Syt1 during Ca 2+ -triggered release, even if their function is normally coupled to this Ca 2+ sensor. To test this hypothesis, we compared the Ca 2+ -evoked release efficacy of Syt1-deficient neurons 38 to that of neurons lacking both Syt1 and complexin genes.
We generated Syt1/CplxI/CplxII TKO mice, and they died shortly after birth, sooner than Syt1 KO and CplxI/II DKO mice, suggesting a more severe phenotype than Syt1 KO and CplxI/II DKO mice. The synaptic characteristics of CplxII KO neurons are indistinguishable from those of WT neurons 18 . We thus used CplxII KO neurons as controls and compared them to CplxI/CplxII DKO, Syt1/CplxII DKO and Syt1/CplxI/CplxII TKO neurons. The fast, synchronous evoked EPSCs were reduced in CplxI/CplxII DKO neurons and were diminished in Syt1/CplxII DKO and Syt1/CplxI/CplxII TKO neurons compared to the control neurons (Fig. 7a,b) . The RRP sizes were not significantly different among all groups (P > 0.05, data not shown). The P vr values of CplxI/CplxII DKO and Syt1/CplxII DKO neurons are ~58% and ~33% of that of the control value, respectively (Fig. 7c) . Notably, the P vr of Syt1/CplxI/CplxII TKO is further reduced to 18% of the control value and 56% of the Syt1/CplxII DKO value (P < 0.01 for Syt1/CplxI/CplxII TKO versus Syt1/CplxII DKO). These results indicate that both complexins and Syt1 regulate the efficacy of Ca 2+ -triggered release and that complexins can facilitate Ca 2+ -evoked release independently of Syt1 (refs. 24,26) , although this does not imply that complexins bind Ca 2+ .
However, we do find evidence indicating a genetic interaction between complexins and Syt1. Loss of one functional Syt1 allele has no effect on evoked release, as the P vr of Syt1 heterozygous (Syt1-het) neurons is similar to that of WT neurons (Fig. 7d , P = 0.9). However, Syt1 heterozygosity reduced the P vr of evoked release in the absence of complexins, because the P vr of Syt1-het/CplxI KO/CplxII KO neurons decreased by ~36% compared to that of CplxI/CplxII DKO neurons (Fig. 7e) . Conversely, CplxI heterozygosity did not significantly reduce P vr in Syt1/CplxII DKO neurons (P vr : Syt1 KO/CplxIhet/CplxII KO, 3.8 ± 0.5% versus Syt1 KO/CplxII KO, 4.2 ± 0.3%, P = 0.5). These data show that half the amount of Syt1 is normally sufficient to maintain WT-like evoked release but becomes 
DISCUSSION
Complexin function was initially associated with two hallmarks: a specific active role in the Ca 2+ -triggering step of release 18 and the binding of its central α-helix to the SNARE complex 13, 14 . It later became clear that complexin function involves both facilitatory and inhibitory functions. A popular model predicts that complexins inhibit release before Ca 2+ influx, and Syt1 releases this inhibition 22, 23, 28 , but it is difficult to account for the facilitatory function of complexins based solely on this model. The finding that the complexin N terminus is essential for its function showed that a crucial interaction for complexins remained to be uncovered 26 . The complexin N terminus was recently proposed to assist the SNAREs in exerting force on the membranes 17 , but no biochemical data supporting this notion was described. Our data now reveal three novel aspects fundamental for understanding complexin function: the interaction of the complexin N terminus with the SNARE complex C terminus, the identification of a role for complexins in a priming step before Ca 2+ influx and the observation that complexin function can be at least partially separated from the action of Syt1. Our hypertonic-sucrose data indicate that complexins facilitate release by lowering the energy required for fusion, thus enhancing vesicle fusogenicity. This provides a natural explanation for why complexins facilitate both evoked and spontaneous release in mouse hippocampal neurons 19 . Moreover, we identified two residues in the CplxI N terminus that are essential for binding to the SNARE complex C terminus and for the active function of complexins. This correlation suggests that complexins enhance vesicle fusogenicity by binding the SNARE complex not only through the central α-helix but also through the N terminus. As binding of complexins to the SNARE complex through the central α-helix places complexins right at the site of fusion, the SNAREs and the membranes are natural targets for the complexin N terminus to perform its function. Indeed, the stimulatory effects of complexins in some reconstitution experiments 24, 25 indicate that their active function can be at least partially recapitulated in these in vitro systems containing only lipids and SNAREs. Our results favor the notion that binding of the complexin N terminus to the SNARE complex C terminus underlies in part its active role in membrane fusion and neurotransmitter release. However, we cannot rule out the possibility that, in the context of trans SNARE complexes assembled between two membranes, the complexin N terminus may also interact with the lipids.
The finding that the M5E K6E mutation abrogates the complexin facilitatory function in each of the electrophysiological parameters that we measured (Figs. 2, 3 and 6) highlights the functional importance of the complexin N terminus. We propose that the interaction between the complexin N terminus and the SNARE complex C terminus has two roles (Fig. 8) . First, as the C terminus of the SNARE complex is not very stable 13 and its assembly is expected to help overcome the energy barrier for membrane fusion, our findings naturally lead to the notion that the complexin N terminus may promote membrane fusion by stabilizing the SNARE complex C terminus. Second, the complexin N terminus may help release the inhibition caused by the accessory α-helix, switching the release machinery from an inhibited state (Fig. 8b) to an activated state (Fig. 8c,d) . This model can explain the stimulatory 24, 25 and inhibitory 22, 23 effects of complexins in reconstitution assays and is supported by multiple physiological observations.
The finding that removal of the N terminus abolishes the rescue activity of CplxI, but that deletion of the N terminus and the accessory α-helix leads to partial rescue 26 , together with examination of the crystal structure of CplxI bound to the SNARE complex (Fig. 5b) suggests that the accessory α-helix may inhibit release by replacing the C terminus of the synaptobrevin-2 SNARE motif in the four-helix bundle, thus hindering C-terminal assembly of the SNARE complex 26 (Fig. 8b) . This proposal has recently been supported by the finding that complexins bind syntaxin-1-SNAP-25 complexes 24, 39, 40 as well as by cell-cell fusion data 41 . Our model postulates that the complexin N terminus helps release the inhibition by the accessory helix, which is supported by the recent electron paramagnetic resonance data 42 and could arise because binding of the complexin N terminus to the SNARE complex may require dissociation of the accessory α-helix. However, this disinhibition activity alone cannot explain why removal of the CplxI N terminus and accessory α-helix leads to only partial rescue 26 . Because the complexin central α-helix provides some stabilization for the SNARE complex 13 , but this effect is not sufficient for the complexin facilitatory function 26 , our model proposes that the activating function of the complexin N terminus involves stabilization of the SNARE complex C terminus. Note that, in our model, binding of the complexin central α-helix to the SNARE complex also plays a key role by strategically positioning the accessory α-helix and the N terminus near their binding sites on the SNAREs 26 .
This model also provides a clear explanation for the notion that complexin function does not depend strictly on the Syt1-Ca 2+ complex, as shown by the finding that lack of complexins leads to impaired spontaneous release 19 (Fig. 3) , decreased sensitivity of release to 250 mM sucrose (Fig. 6 ) and exacerbated impairment of release observed in the absence of Syt1 (Fig. 7a-c) . Several studies indicated a tight link between the functions of both proteins 22, 23, 28 , and biophysical data 28 indicated The complexin central α-helix binds the partially assembled SNARE complex and helps to assemble the SNARE complex further. At the same time, the complexin accessory α-helix replaces the C terminus of the synaptobrevin-2 SNARE motif in the four-helix bundle, preventing C-terminal assembly 26, 41 . (c) The complexin accessory α-helix is released from the SNARE complex by the complexin N terminus, Syt1/Ca 2+ , or both, allowing full assembly of the SNARE complex C terminus. (d) The SNARE complex is fully assembled. Binding of the complexin N terminus to the SNARE complex C terminus is proposed to help release the inhibition of the accessory α-helix and/or to stabilize the C terminus of the SNARE complex to assist in exerting force on the membranes. Note that the location of the complexin N terminus is only tentative in c and d. The complexin C terminus is not shown for simplicity. a r t i c l e s that complexin is displaced from the SNARE complex by Syt1, but this competition may only be partial, and both proteins may be able to bind simultaneously to the SNARE complex 30 . Moreover, the key role of the N terminus for complexin function argues against the notion that complexins are released from the SNARE complex 26 . In our model, the stabilizing effect of the complexin N terminus on the SNARE complex C terminus is Ca 2+ -independent, and the release of the inhibition of the accessory α-helix can be promoted by the complexin N terminus without an absolute requirement for Syt1 and Ca 2+ . In fact, although most current models assume that the transition from state B to state C (Fig. 8) occurs upon Ca 2+ influx, an alternative possibility is that these two states are in equilibrium in primed vesicles before Ca 2+ influx. In our model, vesicles in all states can undergo spontaneous, hypertonically induced or Ca 2+ -triggered fusion, and complexins increase fusogenicity of all states. This proposal can explain the observation that complexins and Syt1 interact genetically, yet their functions are not strictly interdependent. Nevertheless, Syt1 could still help promote the transition from state B to state C upon Ca 2+ influx, cooperating with the complexin N terminus in releasing the accessory α-helix from the SNARE complex.
Clearly, further research will be required to fully elucidate how complexins function, but it now seems clear that complexins orchestrate synaptic-vesicle fusion through built-in facilitatory and inhibitory mechanisms, and complexins' facilitatory function depends on their N-terminal interaction with the C terminus of the SNARE complex.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. 
ONLINE METHODS
Viral constructs and production. WT rat CplxI was used to generate all mutant CplxI variants 26 . Myc-tagged CplxI variants were generated by fusing a linker (SGGSGGTGG) followed by a c-myc (EQKLISEEDL) to the C terminus of CplxI variants. The cDNAs were subsequently cloned into a Semliki Forest virus (SFV) vector described previously 26 . A lentiviral vector expressing WT DmCplx was described previously 27, 43 . The corresponding vectors without CplxI or DmCplx served as control constructs. Virus production and infection were performed as described 27, 44 with modification. The procedures are described in detail in Supplementary Methods. Mice, neuronal culture, western blotting and immunocytochemistry. CplxI/II DKO and CplxI/II/III TKO mice were obtained as described 18, 19 . Syt1/CplxI/ CplxII TKO mice were obtained by interbreeding of mice homozygous for the CplxII mutations and heterozygous for both the Syt1 mutation 38 and the CplxI mutation. All procedures to maintain and use these mice were approved by the Institutional Animal Care and Use Committee for Baylor College of Medicine and Affiliates. Primary neuronal culture, western blotting, immunocytochemistry and confocal microscopy were performed as described 26 .
Electrophysiology of cultured neurons. Whole-cell voltage clamp recordings were performed at room temperature (23-24 °C) on cultured neurons during 9-14 d in vitro as described 19 . SFV rescue experiments were performed between 9 h and 12 h after neurons were infected with SFV. For hippocampal glutamatergic neurons, the patch pipette solution contained: potassium gluconate, 146 mM; HEPES, 17.8 mM; EGTA, 1 mM; MgCl 2 , 0.6 mM; ATP-Mg 2+ , 4 mM; GTP-Na + , 0.3 mM; phosphocreatine, 12 mM; phosphocreatine kinase, 50 units per ml; 300 mM mOsm, pH 7.4. For striatal GABAergic neurons, the patch pipette solution contained: KCl, 136 mM; HEPES, 17.8 mM; EGTA, 1 mM; MgCl 2 , 0.6 mM; ATP-Mg 2+ , 4 mM; GTP-Na + , 0.3 mM; phosphocreatine, 12 mM; phosphocreatine kinase, 50 units per ml; 300 mM mOsm, pH 7.4. The standard extracellular solution contained: NaCl, 140 mM; KCl, 2.4 mM; HEPES, 10 mM; glucose, 10 mM; CaCl 2 , 4 mM; MgCl 2 , 4 mM; 300 mM mOsm, pH 7.4. For Ca 2+ -sensitivity experiments, Mg 2+ concentration in extracellular solution was kept at 1 mM, and Ca 2+ concentration was 12 or 1 mM. Hypertonic sucrose solutions were made by adding 500 mM or 250 mM sucrose to the standard extracellular solution.
Basal evoked EPSC, RRP, paired-pulse ratio, apparent Ca 2+ sensitivity of release and mEPSC were measured as described 19, 26 with minor modifications. The details are described in Supplementary Methods.
To measure the synaptic-vesicle fusogenicity, 250 mM sucrose solution was directly applied onto the neuron for 10 s (hippocampal glutamatergic neurons) or 12 s (striatal GABAergic neurons). The charge transfer of the transient synaptic current was measured and divided by the RRP size from the same neuron to obtain the fraction of RRP released by 250 mM sucrose solution. The onset of sucrose response was visually identified. The time from the onset of the sucrose solution application to the onset of the response was measured (T 1 ). An 'open tip' response was used to determine the time for sucrose solution to reach the neuron (T 2 ). The sucrose response onset latency was defined as the interval between the time when sucrose solution reaches the neuron and the onset time of sucrose response (T 1 -T 2 ). To determine the peak release rate, synaptic current traces were first digitally filtered at 10 Hz. The peak amplitude of sucrose response was then divided by the RRP size from the same neuron to obtain the peak release rate. For the experiments in hippocampal mass-cultured neurons, 0.5 µM tetrodotoxin and 15 µM gabazine were included in the sucrose solutions. Data were analyzed offline using AxoGraph X (AxoGraph Scientific). Statistical significances were tested using the Student's t-test, the nonparametric Mann-Whitney test or one-way analysis of variance.
Recombinant protein expression and purification. Full-length rat syntaxin-1 and rat SNAP-25 used to generate the membrane-bound SNARE complex were coexpressed and purified as described previously 45, 46 . A fragment of rat synaptobrevin-2 (residues 1-96) was used for membrane-bound SNARE complex. For soluble SNARE complexes, we used fragments spanning rat syntaxin-1A 191-253 , rat synaptobrevin-2 , human SNAP-25 and human SNAP-25 . All fragments were expressed and purified as described 13, 30 . Full-length rat CplxI and its mutants were expressed and purified as described 9 . SNARE complexes were assembled as described 13 . Labeling of CplxI 2-82 A12C with MTSL was performed as described 34 .
Liposome reconstitution. Liposome reconstitution was performed using the direct method 46 with a lipid mixture of 85% (w/w) 1-palmitoyl-2-oleoyl-snglycero-3-phosphocholine and 15% (w/w) 1,2-dioleoyl-sn-glycero-3-[phosphol-serine] (Avanti Polar Lipids). The protein:lipid molar ratio was 1:1,000.
NMR spectroscopy. All NMR spectra were performed on Varian INOVA 600 MHz spectrometers. Samples for experiments with proteoliposomes and control contained 2 µM 15 N-CplxI without or with proteoliposomes (3 µM SNARE complex, 3 mM lipid) in buffer containing 20 mM HEPES, 100 mM KCl, 1 mM EDTA and 1 mM TCEP. Acquisition time for each 1 H-15 N HSQC spectrum was ~12 h on a cold probe. Additional 1 H-15 N spectra were acquired with samples containing 5 µM 15 N-CplxI and 3 mM lipids or 80 µM 15 N-CpxI and 120 µM SNARE complex. 1 H-15 N TROSY-HSQC spectra of soluble SNARE complexes where each SNARE motif was individually 2 H, 15 N-labeled (~80 µM) were acquired as described 13 in the presence 100 µM MTSL-CplxI 2-82 A12C before and after addition of 1 mM dithionite.
Fluorescence spectroscopy. Fluorescently labeled CpxI A12C C105S was obtained by reacting CplxI A12C C105S with the cysteine-specific reagent N,N '-dimethyl-N-(iodoacetyl)-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) ethylenediamine (NBD) as described 33 . Fluorescence spectra were acquired on a PTI spectrofluorimeter with excitation at 465 nm using 50 nM NBD-labeled CpxI A12C C105S alone or in the presence of 2 µM soluble SNARE complex, SNARE complex proteoliposomes (3 µM SNAREs, 3 mM lipids) or plain liposomes (3 mM lipids).
